Phase 3, randomized, double-blind, placebo controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naive patients with acute myeloid leukemia.

被引：5
|
作者：
Potluri, Jalaja
Xu, Tu
Hong, Wan-Jen
Mabry, Mack H.
机构：
[1] AbbVie Inc, Chicago, IL USA
[2] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS7069
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7069
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Li-xia Zhu
    Rong-rong Chen
    Lu-lu Wang
    Jia-nai Sun
    De Zhou
    Li Li
    Jie-jing qian
    Yi Zhang
    Hong-yan Tong
    Wen-juan Yu
    Hai-tao Meng
    Wen-yuan Mai
    Wan-zhuo Xie
    Jie Jin
    Xiu-jin Ye
    Hong-hu Zhu
    Supportive Care in Cancer, 2022, 30 : 7031 - 7038
  • [42] Outpatient Maintenance Therapy of Venetoclax Combined with Azacitidine in Patients with Acute Myeloid Leukemia- a Real-World Retrospective Study
    Nie, Zi-Yuan
    Ren, Jinhai
    Zhan, Ying
    Zhang, Xiaolei
    Li, Jinao
    Guo, Xiaoling
    BLOOD, 2024, 144 : 5941 - 5941
  • [43] Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia:a Phase III, Prospective, Multicenter, Randomized Controlled Trial
    Zhou, Zeping
    Tan, Yaxian
    Zhao, Xingli
    Suo, Xiaohui
    Bai, Guanchen
    Bai, Yanliang
    Luo, Yunya
    Lu, Xinxiao
    Yuan, Linyu
    Zhang, Congcong
    Li, Yinling
    Gao, Sifeng
    Zhang, Jilei
    Peng, Hongling
    Guo, Pengxiang
    Mi, Yingchang
    Liu, Kaiqi
    BLOOD, 2024, 144 : 6035 - 6036
  • [44] Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study
    Lou, Yinjun
    Shao, Li
    Mao, Liping
    Lu, Ying
    Ma, Yafang
    Fan, Cuihua
    Jiang, Huifang
    Li, Jianhu
    Jin, Jie
    LEUKEMIA RESEARCH, 2020, 91
  • [45] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
    Yacoub, Abdulraheem
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 115 - 116
  • [46] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
    Yacoub, Abdulraheem
    Erickson-Viitanen, Susan
    Zhou, Feng
    Assad, Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.
    Fong, Chun Yew
    Wei, Andrew H.
    Frattini, Mark G.
    Jacoby, Meagan
    Borate, Uma
    Gotze, Katharina S.
    Garcia, Jacqueline Suen
    Pollyea, Daniel Aaron
    Holes, Leanne
    Zhou, Ying
    Fakouhi, Kaffa Mussumeh
    Leverson, Joel
    Harb, Jason G.
    Agarwal, Suresh K.
    Attarchi, Faraneh
    Mabry, Mack H.
    Hong, Wan-Jen
    Jahn, Thomas Michael
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
    Fathi, Amir T.
    Fell, Geoffrey G.
    El-Jawahri, Areej
    Perl, Alexander E.
    Jonas, Brian A.
    Dias, Ajoy L.
    Mims, Alice S.
    Borate, Uma
    Ragon, Brittany Knick
    Grunwald, Michael R.
    Peters, Mary Linton B.
    Graubert, Timothy A.
    Amrein, Philip C.
    Hock, Hanno R.
    Brunner, Andrew M.
    Hobbs, Gabriela S.
    Narayan, Rupa
    Neuberg, Donna S.
    Aldoss, Ibrahim
    BLOOD, 2022, 140 : 3284 - 3286
  • [49] A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
    Daver, Naval
    Liu, Ke
    Werneke, Scott
    Rustia, Evelyn
    Ramsingh, Giri
    Vyas, Paresh
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S5
  • [50] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
    Liu, Qingyang
    Yang, Jingjing
    Lv, Lei
    Zhang, Xiawei
    Li, Meng
    Xu, Lingmin
    Huang, Sai
    Jing, Yu
    Dou, Liping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
12345